Moderna seeks emergency authorization for omicron COVID booster for children
Moderna announced Friday that it has requested emergency use authorization for its omicron COVID-19 booster shots for children aged 6-17 years old.
Driving the news: The application for the bivalent vaccine for children ages 6 months to under 6 years old is expected to be completed later this year, the company said on Twitter.
- The Centers for Disease Control and Prevention said this week that it anticipates recommending the updated boosters for kids in early- to mid-October, pending authorization from the Food and Drug Administration.
Of note: Doses of bivalent Moderna vaccine for children aged 6-17 years are expected to come from the same vials currently used for vaccinating adults, per the CDC.
- The vaccine for children aged 6-11 years is expected to be half the volume and dosage that is currently authorized for adults, according to the CDC.
- The vaccine for those aged 12-17 years is expected be the same volume and dosage as is currently authorized for individuals aged 18 years and older.
Reality check: Less than 325,000 of America's youngest children were fully vaccinated as of this week — and hesitancy continues to dog the pandemic response, Axios' Erin Doherty reports.
- Children under 5 have had the highest rates of hospitalization from COVID among youth, per the CDC.
Background: The FDA authorized COVID-19 vaccines for kids between 6 months and 5 years in June — nearly a year and a half after the first vaccines were made available for at-risk adults.
Moderna did not immediately respond to Axios' request for comment.
Axios' Adriel Bettelheim contributed to this report.